Dupuytren's Contracture

Dupuytren's contracture, also called Dupuytren's disease or palmar fibromatosis, is a benign but progressive fibrosis of the palmar aponeurosis — the fibrous sheet that lies just under the skin of the palm. Firm nodules develop, evolve into taut cords and can eventually bend one or more fingers into a fixed flexion that no longer straightens.

It is most common in adults of Northern European ancestry over the age of 50, more frequent in men, and has a strong hereditary component. The condition itself is not dangerous and does not shorten life expectancy, but advanced forms can significantly impair daily activities such as shaking hands, wearing gloves, washing or reaching into pockets.

This dossier is meant for patients, caregivers and healthcare professionals looking for a clear, neutral, evidence-based summary of the disease, its diagnosis and its validated treatments.

• Dupuytren's contracture is a slowly progressive fibrosis of the palmar aponeurosis (palmar fascia), also called Dupuytren's disease or palmar fibromatosis.
• It typically starts as a firm palm nodule, evolves into a fibrous cord and can bend one or more fingers permanently — most often the ring and little fingers.
• The exact cause is unknown; genetics, male sex, age > 50, Northern European ancestry, diabetes, tobacco and alcohol are recognised risk factors.
• Diagnosis is clinical. The tabletop test (inability to lay the hand flat on a table) is a simple, reliable red flag.
• Validated treatments include observation, needle aponeurotomy, collagenase injections and open surgery (limited fasciectomy). No dietary supplement is a validated treatment.

Dupuytren's contracture is a fibroproliferative disorder of the palmar fascia. Fibroblasts in the aponeurosis differentiate into contractile myofibroblasts that produce excess type-III collagen and actively pull on the tissue. Over time, this remodelling forms palpable nodules and longitudinal cords that shorten the aponeurosis and bend the fingers.

Histologically, the disease evolves through three phases described by Luck: a proliferative phase (myofibroblast expansion), an involutional phase (dense collagen deposition and active contraction) and a residual phase (mature, acellular fibrous cords). Clinically, these phases roughly map to nodule, cord and fixed contracture.

It belongs to the same family as Ledderhose disease (plantar fibromatosis) and Peyronie's disease (fibromatosis of the tunica albuginea) and can coexist with them.

Healthy hand

Supple aponeurosis · full finger extension

Affected hand

Nodule, fibrous cord, finger contracture

Symptoms usually appear gradually, without pain, and progress over months to years. The three cardinal features are palm nodules, fibrous cords and finger contracture.

Early-stage Dupuytren's contracture is defined by a palm nodule or mild skin thickening without a fixed finger contracture. At this stage, the fingers still extend fully and daily activities are not impaired.

Detection is often incidental — a partner or a clinician notices a firm lump in the palm. Skin pitting or dimpling is a subtle but characteristic clue. Most early nodules progress slowly; a minority remain stable for years or even indefinitely.

Dupuytren's contracture typically appears as a firm, painless lump on the palm — most often at the base of the ring finger — sometimes with dimpling of the overlying skin. As the disease progresses, a rope-like cord becomes visible running from the palm toward the finger, and the finger itself becomes progressively bent, unable to be fully straightened.

In advanced disease, the affected fingers are held in permanent flexion, with the fingertips curling toward the palm. The palm skin often looks puckered and thickened. In very severe forms, hygiene of the palm becomes difficult and skin maceration can occur.

Any finger can be affected, but the ring finger (4th) is the most common, followed by the little finger (5th) and the middle finger (3rd). The thumb and index finger are involved less often, generally in more aggressive forms.

Bilateral involvement is frequent; disease often appears in the second hand within a few years of the first. Involvement of multiple fingers on both hands, especially in a younger patient, defines a Dupuytren diathesis: a more aggressive phenotype with higher recurrence after treatment.

The exact cause of Dupuytren's contracture is unknown. It results from the interaction between a strong genetic predisposition and several acquired risk factors. At the tissue level, the trigger is an abnormal fibroproliferative response of palm fibroblasts to unknown local signals.

Genetic studies (GWAS) have identified variants in the Wnt signalling pathway associated with Dupuytren's disease. Fibroblasts differentiate into myofibroblasts expressing α-smooth muscle actin, driven by TGF-β1, TNF and oxidative stress signals. These cells actively contract and deposit excess collagen, creating the palpable cord.

Several factors independently increase the risk of developing Dupuytren's contracture. Most are non-modifiable (genetics, sex, age), but a few lifestyle factors (tobacco, alcohol, diabetes control) can be acted on.

Dupuytren's contracture progresses in an unpredictable, non-linear way. Many patients remain at the nodule stage for years or decades, while others develop finger contractures within months. Four stages describe the typical clinical trajectory.

1. Stage 1

   Palm nodule

   Firm painless lump; extension preserved; tabletop test negative.

2. Stage 2

   Skin changes and early cord

   Skin dimpling, pretendinous band appearing; mild MCP flexion possible.

3. Stage 3

   Established contracture

   Well-formed cord; fixed MCP and/or PIP flexion; tabletop test positive.

4. Stage 4

   Severe contracture

   Marked flexion of one or more fingers; significant functional impairment.

Dupuytren's contracture is a benign condition and does not shorten life expectancy on its own. Some cohort studies have reported a modest association with cardiovascular disease and all-cause mortality, but this most likely reflects shared risk factors (age, sex, diabetes, alcohol, tobacco) rather than a direct effect of Dupuytren's disease.

Patients with Dupuytren's contracture should nevertheless benefit from the same cardiometabolic prevention as any adult with similar risk factors: blood-pressure control, diabetes management, smoking cessation and moderation of alcohol.

Several hand conditions can be confused with Dupuytren's contracture, especially at an early stage. A hand specialist can differentiate them clinically.

Diagnosis is clinical. The physician takes a history, inspects and palpates the palm and fingers, and quantifies the finger contracture. No imaging or blood test is required in the vast majority of cases.

You should see a hand surgeon or an orthopaedic hand specialist as soon as a finger contracture appears, the tabletop test becomes positive, or the disease starts to interfere with daily activities. Earlier referral is also appropriate if you have a young age at onset, bilateral disease or a strong family history.

There is no single best treatment. Guideline-based care combines observation, hand therapy, needle aponeurotomy, collagenase injections and surgery. Choice depends on the severity, the joints affected, recurrence risk and patient preferences.

The three main procedural treatments have different profiles in terms of invasiveness, recovery, effectiveness and recurrence. This side-by-side comparison summarises the practical differences.

Because Dupuytren's disease is a chronic biological process, recurrence is possible after any treatment. Rates depend on the technique, the joints treated and patient-related factors.

• Needle aponeurotomy: recurrence around 50–65% at 5 years (van Rijssen et al., 2012).
• Collagenase injections: intermediate recurrence, often around 35–50% at 5 years depending on definitions.
• Limited fasciectomy: lowest recurrence, roughly 20–30% at 5 years in most series.

A Dupuytren diathesis (young age, bilateral disease, family history, Ledderhose disease, knuckle pads) is the strongest predictor of recurrence, regardless of the treatment used.

Exercises and stretching cannot reverse an established Dupuytren cord. However, structured hand therapy plays a central role after needle aponeurotomy, collagenase injections or surgery, to preserve range of motion, control oedema and prevent stiffness.

A hand therapist typically prescribes gentle extension exercises, oedema-control techniques and, when appropriate, a static extension splint worn at night for several weeks or months. Aggressive or painful stretching should be avoided as it can increase inflammation.

No specific food is proven to cause, prevent or cure Dupuytren's contracture. There is no scientifically validated "Dupuytren diet". General health measures — a balanced Mediterranean-style diet, tight diabetes control, moderation of alcohol and avoidance of tobacco — remain reasonable recommendations, mostly for their overall cardiometabolic benefit.

Some patients ask about vitamin E, N-acetylcysteine, curcumin or other antioxidant supplements. Older trials of vitamin E in Dupuytren's disease did not confirm a clinical benefit. Newer molecules are studied only at the preclinical level (see below).

Research on Dupuytren's contracture focuses on the biology of myofibroblasts, the role of TGF-β1 and TNF, prognostic biomarkers, and new pharmacological approaches aimed at slowing early-stage disease rather than treating advanced contractures.

• Anti-TNF (adalimumab). The RIDD trials (Nanchahal et al., 2018 and 2022) provided randomised evidence that intranodular adalimumab reduces nodule size and softens tissue in early-stage disease. Long-term effects on progression to contracture are still being evaluated.
• Genetics. Genome-wide association studies have confirmed Wnt-pathway involvement, opening the way to targeted therapies (Dolmans et al., 2011).
• Refinements of collagenase and needle aponeurotomy. Ongoing work refines patient selection, technique and post-procedural care to reduce recurrence.
• Antioxidant and anti-fibrotic pathways. Preclinical work on ROS, TGF-β1 and NF-κB continues to inform hypotheses on how nutritional or pharmacological modulation might influence fibrosis.

Dietary supplements are not a validated treatment for Dupuytren's contracture. Some molecules — antioxidants, polyphenols — are studied for their potential role in oxidative stress, inflammation and fibrosis pathways, but clinical evidence remains limited or absent. They cannot, on their own, prevent, halt or cure the disease.

For a detailed cross-cutting analysis of nutritional approaches studied in fibroproliferative diseases and their levels of evidence, see our dossier on natural approaches and fibroproliferative diseases.

Current clinical evidence for these compounds as a treatment of Dupuytren's contracture is very limited. Dietary supplements do not replace medical care and should be discussed with a healthcare professional before use.

A selection of reference publications and international guidelines used to write this dossier. The list is not exhaustive and will be enriched as the dossier is updated.

Dupuytren's contracture is a common, benign but progressive fibrosis of the palmar aponeurosis. Modern care combines observation of early disease with minimally invasive procedures (needle aponeurotomy, collagenase) and, when necessary, hand surgery, all tailored to the joints affected, the severity of the contracture and the patient's expectations.

AARO LAB focuses on the biological mechanisms involved in fibrosis, oxidative stress and tissue integrity. Dietary supplements are not a treatment for Dupuytren's disease and cannot replace an evaluation by a hand specialist.